A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Incidence of Endometrial Hyperplasia and Changes in Bone Mineral Density

Outcome Time Frame:

1 Year

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

3115A1-3307

NCT ID:

NCT00808132

Start Date:

January 2009

Completion Date:

February 2011

Related Keywords:

• Menopause
• Osteoporosis
• Postmenopausal Women
• Bazedoxifene/Conjugated Estrogens
• Endometrial Hyperplasia
• Osteoporosis
• Osteoporosis, Postmenopausal
• Adenoma